Enzon Pharmaceuticals Inc ENZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.08
- Day Range
- $0.08–0.08
- 52-Week Range
- $0.06–0.22
- Bid/Ask
- $0.08 / $0.09
- Market Cap
- $6.29 Mil
- Volume/Avg
- 33,763 / 18,671
Key Statistics
- Price/Earnings (Normalized)
- 8.48
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- http://www.enzon.com
Competitors
Valuation
|
Metric
|
ENZN
|
VRTX
|
RHHBY
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.48 | 26.42 | 10.92 |
Price/Book Value | 1.80 | 5.89 | 5.44 |
Price/Sales | — | 10.61 | 2.85 |
Price/Cash Flow | 5.18 | 27.55 | 10.47 |
Price/Earnings
ENZN
VRTX
RHHBY
Financial Strength
|
Metric
|
ENZN
|
VRTX
|
RHHBY
|
|---|---|---|---|
Quick Ratio | 27.43 | 3.60 | 0.99 |
Current Ratio | 27.62 | 3.99 | 1.35 |
Interest Coverage | — | 86.38 | 14.93 |
Quick Ratio
ENZN
VRTX
RHHBY
Profitability
|
Metric
|
ENZN
|
VRTX
|
RHHBY
|
|---|---|---|---|
Return on Assets (Normalized) | 2.92% | 19.46% | 17.03% |
Return on Equity (Normalized) | 45.09% | 25.47% | 53.42% |
Return on Invested Capital (Normalized) | −13.57% | 21.34% | 26.30% |
Return on Assets
ENZN
VRTX
RHHBY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nwqkjzrx | Swf | $570.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vyqjfbr | Xdlxdm | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sfpvjmjlf | Rfffj | $99.6 Bil | |
MRNA
| Moderna Inc | Wbjbytwk | Pxsn | $42.7 Bil | |
ARGX
| argenx SE ADR | Rzgrmgzh | Vdvf | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Bznpdytzw | Nfk | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fztkksjx | Lwvvtq | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kpwwgzpy | Jdmngt | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mcqzdczx | Jnlcm | $12.7 Bil | |
INCY
| Incyte Corp | Zlcxcyy | Fmkvvkr | $11.9 Bil |